U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H34O8
Molecular Weight 474.5434
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHYLPREDNISOLONE HEMISUCCINATE

SMILES

C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)C=CC(=O)C=C14

InChI

InChIKey=IMBXEJJVJRTNOW-XYMSELFBSA-N
InChI=1S/C26H34O8/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31)/t14-,16-,17-,19-,23+,24-,25-,26-/m0/s1

HIDE SMILES / InChI

Molecular Formula C26H34O8
Molecular Weight 474.5434
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html

Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist.

Originator

Curator's Comment: # Pfizer

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.4 nM [EC50]
1.07 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MEDROL

Approved Use

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Launch Date

1957
Primary
MEDROL

Approved Use

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Launch Date

1957
Primary
MEDROL

Approved Use

INDICATIONS AND USAGE MEDROL Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Launch Date

1957
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
213 ng/mL
32 mg single, intravenous
dose: 32 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
931 ng × h/mL
32 mg single, intravenous
dose: 32 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
32 mg single, intravenous
dose: 32 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
23%
METHYLPREDNISOLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg/kg single, intravenous
Highest studied dose
Dose: 1000 mg/kg
Route: intravenous
Route: single
Dose: 1000 mg/kg
Sources:
unhealthy, 0-15 years
Health Status: unhealthy
Age Group: 0-15 years
Sex: M+F
Sources:
1250 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1250 mg, 1 times / day
Sources:
unhealthy, 18–59 years
Health Status: unhealthy
Age Group: 18–59 years
Sex: M+F
Sources:
120 mg 1 times / week multiple, intramuscular
Highest studied dose
Dose: 120 mg, 1 times / week
Route: intramuscular
Route: multiple
Dose: 120 mg, 1 times / week
Sources:
unhealthy, adult
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculous therapy with rifampicin.
1999 Jan
Pulse methylprednisolone therapy for arthritis causing muscle weakness.
1999 Sep
Cytosine arabinoside induced acute interstitial nephritis in a patient treated for refractory anemia with excess of blasts in transformation.
2000 Nov
Stress-induced osteolysis of distal clavicle: imaging patterns and treatment using CT-guided injection.
2001
Lupus nephritis in a child with AIDS.
2001 Apr
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
2001 Apr
Steroid-resistant kidney transplant rejection: diagnosis and treatment.
2001 Feb
[Evaluation of off-pump coronary artery bypass grafting based on systemic inflammatory response syndrome].
2001 Feb
Glucocorticoid inhibition of neuropathic hyperalgesia and spinal Fos expression.
2001 Feb
Effective methylprednisolone dose in experimental crescentic glomerulonephritis.
2001 Feb
Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury.
2001 Feb 15
Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation.
2001 Feb-Mar
Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation.
2001 Feb-Mar
Daclizumab induction therapy in combination with tacrolimus.
2001 Feb-Mar
Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations.
2001 Feb-Mar
Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation.
2001 Feb-Mar
Successful withdrawal of steroid after renal transplantation.
2001 Feb-Mar
Preventive effects of lecithinized superoxide dismutase and methylprednisolone on spinal cord injury in rats: transcriptional regulation of inflammatory and neurotrophic genes.
2001 Jan
New treatment for postherpetic neuralgia.
2001 Jan
Effects of anti-inflammatory drugs on lipopolysaccharide-challenged and -unchallenged equine synovial explants.
2001 Jan
Osteonecrosis of the femoral head after allogeneic bone marrow transplantation.
2001 Jan
The contribution of indocyanine green angiography to the appraisal and management of Vogt-Koyanagi-Harada disease.
2001 Jan
Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury.
2001 Jan 1
Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection.
2001 Jan 27
Recurrent orbital inflammation from metastatic orbital carcinoid tumor.
2001 Mar
Steroids for acute exacerbations of COPD : how long is enough?
2001 Mar
Intrathecal methylprednisolone for postherpetic neuralgia.
2001 Mar 29
Patents

Sample Use Guides

In Vivo Use Guide
Each Medrol Tablet (methylprednisolone) for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone. The initial dosage of Medrol Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated.
Route of Administration: Other
Treatment with methylprednisolone concentrations above 50 uM could ignificantly reduce the proliferation activity of human CLL cell line MEC-1 by 23.34%, 30.73%, 30.57% after 24 h, and 28.48%, 42.35%, 44.56% after 48 h respectively
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:54:43 GMT 2025
Edited
by admin
on Mon Mar 31 17:54:43 GMT 2025
Record UNII
5GMR90S4KN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHYLPREDNISOLONE HYDROGEN SUCCINATE
EP   MART.  
Preferred Name English
METHYLPREDNISOLONE HEMISUCCINATE
USP   USP-RS   WHO-DD  
Common Name English
METHYLPREDNISOLONE HEMISUCCINATE [USP-RS]
Common Name English
METHYLPREDNISOLONE HEMISUCCINATE [USP MONOGRAPH]
Common Name English
METHYLPREDNISOLONE HYDROGEN SUCCINATE [MART.]
Common Name English
METHYLPREDNISOLONE SUCCINATE [JAN]
Common Name English
6-METHYLPREDNISOLONE-21-HEMISUCCINATE
Common Name English
METHYLPREDNISOLONE SUCCINATE
JAN  
Common Name English
Methylprednisolone hemisuccinate [WHO-DD]
Common Name English
METHYLPREDNISOLONE HEMISUCCINATE [USP IMPURITY]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
Code System Code Type Description
MESH
D008776
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201265
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
EVMPD
SUB12159MIG
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
ECHA (EC/EINECS)
220-863-9
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
EVMPD
SUB03256MIG
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
NCI_THESAURUS
C87234
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
WIKIPEDIA
Methylprednisolone succinate
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
DRUG BANK
DB14644
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
CAS
2921-57-5
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
EPA CompTox
DTXSID80183466
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
SMS_ID
100000091386
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
FDA UNII
5GMR90S4KN
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
DRUG CENTRAL
1771
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
RS_ITEM_NUM
1437009
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
PUBCHEM
16923
Created by admin on Mon Mar 31 17:54:43 GMT 2025 , Edited by admin on Mon Mar 31 17:54:43 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY